Advanced searches left 3/3

Vitamin D - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

Vitamin D and Omega-3 Trial (VITAL)

Vitamin D and marine omega-3 fatty acid supplements are found in a randomized clinical trial of vitamin D and marine omega-3 fatty acid supplements in the primary prevention of cancer and cardiovascular disease. Existing evidence from laboratory experiments, epidemiologic study, small primary prevention studies, and/or large secondary prevention studies shows that these nutritional supplements can reduce the risk of cancer or CVD, but large primary prevention trials with adequate dosing in general populations are lacking. Vitamin D and omega-3 fatty acid supplementation in the United States were tested on a human subject in cancer and CVD. Vitamin D and omega-3 fatty acid supplements, ethnicity, and body mass index also affected cancer and CVD risk, as well as baseline blood counts or intake of vitamin D and EPA+DHA, race/ethnicity, and calcium intake, as well as age, sex, sunlight exposure, calcium intake, and baseline risk factors for cancer and CVD. Individuals were randomly assigned to one of four groups, daily vitamin D and omega-3; daily vitamin D placebo and omega-3; or daily vitamin D placebo and omega-3 placebo; or daily vitamin D placebo and omega-3 placebo. Participants in both groups took two pills each day: one softgel with either vitamin D or vitamin D placebo mixed, and another capsule with either omega-3 or omega-3 placebo.

Source link: https://clinicaltrials.gov/ct2/show/NCT01169259


Vitamin D Deficiency in Adults Following a Major Burn Injury

Vitamin D deficiant burn patients are afflicted with Vitamin D-deficiency burn patients at a single site double blind controlled trial versus a higher dose compared to a higher dose. People who meet the qualifying criteria will be randomly assigned to either low or high doses of Vitamin D, and control is low dose Vitamin D.

Source link: https://clinicaltrials.gov/ct2/show/NCT05084248


Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

Vitamin D3, omega-3 fatty acids, or both can reduce diabetic kidney disease formation and progression. OmegA-3 TriaL's ancillary study will determine whether vitamin D3 and omega-3 fatty acids, as well as diabetes prevention and progression of diabetic kidney disease. People with diabetes are at a high risk of kidney disease. In 2005-2008, the prevalence of DKD among people with type 2 diabetes in the United States was 35 percent. DKD is both the leading cause of end stage renal disease in the developed world and a potent promoter of cardiovascular disease risk. Based on the findings of animal-experimental experiments and early human research, vitamin D and omega-3 fatty acids are promising treatments for DKD prevention and treatment. The goal of this ancillary research is to determine and recruit a sub-cohort of VITAL participants with diabetes at baseline and determine the effects of research findings on albuminuria and glomerular filtration rate in this group.

Source link: https://clinicaltrials.gov/ct2/show/NCT01684722


Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Patients with ASCVD who is of particular interest or need special care, such as oral insulin, can have treatment intensified with GLP-1 receptor agonists, SGLT2 inhibitors, or prandial insulin. Many scientific studies have shown that vitamins of both vitamin D and calcium help with modest rises in bone mineral density throughout the skeleton. Vitamin D is involved in numerous brain functions, and vitamin D receptors are present on neurons and glia in areas of the brain that are thought to be involved in depression pathophysiology. According to observational studies, adequate vitamin D levels may reduce the risk of contracting MS and, once MS is present, can minimize the risk of relapse and slow the disease's progression. It promotes insulin secretion via the vitamin D receptor on pancreatic beta cells, and reduces peripheral insulin resistance by vitamin D receptors in muscle and liver. Vitamin D supplementation seems to be related to type 2 diabetes and most other insulin resistance disorders identified to date, in people with prediabetes and most other insulin resistance disorders. According to the author, low vitamin D status appears to be related to type 2 diabetes and most other insulin resistance disorders. Even if their bone mineral content is normal or high, type 2 diabetic patients are at a high risk of bone fractures. Vitamin K promotes osteocalcin deposition and bone formation by steroid and xenobiotic receptors, which can contribute to bone formation. Vitamin K therapy in a type 2 diabetic had the following skeletal benefits: elevated serum osteocalcin, improved collagen cross-link profiles, and increased bone strength, according to a report. These new findings indicate a potential beneficial role of vitamin K supplementation on bone health in type 2 diabetes. Moreover, several human studies have demonstrated the beneficial role of vitamin K supplementation in improving insulin sensitivity and glucose tolerance, reducing the risk of type 2 diabetes. Both animal and human research have shown that vitamin K-dependent protein, control of adipokine levels, antiinflammatory properties, and cholesterol lowering activities may mediate the beneficial function of vitamin K in insulin sensitivity and glucose tolerance. Vitamin K2 intake reduced 7% T2DM risk with each 10-u03 billion g increase, according to studies. Vitamin K2 has a more potent effect than vitamin K1 on T2DM. Vitamin K2 supplemented insulin sensitivity by osteocalcin metabolism, which is why we're talking about it. Vitamin K2 was an IR-modulin and had anti-inflammatory properties as well as cholesterol-lowering effects. Vitamin K supplementation can effectively improve diabetic signs. Vitamin K1, vitamin K2, vitamin K2, and vitamin K3 are among Vitamin K1's popular forms. Vitamin K supplementation in T2DM results in improved glycemic status, according to another research, including FBS, HbA1C, FI, and HOMA-IR. Vitamin K supplementation can also aid in body weight maintenance.

Source link: https://clinicaltrials.gov/ct2/show/NCT05417880


Vitamin D and Some Antioxidants and Trace Elements Levels in Women: Relationship With I.V.F Outcomes

Vitamin D, vitamin E, zinc, and glutathione pertuiting blood and follicular fluid samples of study participants in vitro fertilization after monitoring their health for two to three months before starting the first stage of in vitro fertilization. On the other hand, we will compare the results of these tested parameters with the aforementioned egg quality criteria and the study group's clinical pregnancy rate in the hopes of determining the relationship between these measured results and pregnancy occurrences.

Source link: https://clinicaltrials.gov/ct2/show/NCT05393011


Vitamin D Levels in Umbilical Cord and It's Impact on Infant and Children's Health: A Cohort Study (VITADi Study)

Women in the third semester of pregnancy who have agreed to be included with their babies in this research are women in the third semester of pregnancy. Blood testing will also be done to determine complete blood count, ferritin, Fe serum, vitamin D, calcium, parathyroid hormone, IL-6 and IL-10. The babies who met the criteria will also be included in this analysis after the subjects give birth. Measurement of birth weight, birth length, and head circumference will be carried out alongside blood testing by taking 3 ml of blood from umbilical cord, 1,5 ml each, to determine ferritin, Fe serum, vitamin D receptors, IL-6 and IL-10. Blood sampling will be done again at 6 months old by taking 3 ml of the blood, 1,5 ml each to determine the complete blood count, and the other 1,5 ml to analyze ferritin, Fe serum, vitamin D receptors, IL-6, and IL-10. The collected data will then be grouped based on the purpose and type of data, followed by univariate analysis and bivariate analysis. Meanwhile, bivariate analysis such as Wilcoxon test will be used to analyze results with independent variables with an ordinal/numeric scale, although the results are not normally distributed and have different variances. A Mann-Whitney test will also be administered to compare ordinal or numeric scale variables whose results are not widely distributed and have disparities between two unpaired groups.

Source link: https://clinicaltrials.gov/ct2/show/NCT05419973


Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Since PDT is nonmutagenic, nonscarring, and can be safely repeated many times, the overall effect is that it can provide significant relief to patients with Basal Cell Nevus Syndrome and multiple BCC tumors. Vitamin D may be useful as a neoadjuvant to increase tumor responses to PDT, according to the specific study's findings. Patients with BCNS and multiple BCC, or healthy patients with at least three BCC tumors, will be accepted. Study Design: In this clinical study, each patient will exercise either his or her own responsibility with regard to BCC tumor responsiveness to neoadjuvant D3 supplementation. Patients in Group A will receive D3 pills prior to the first PDT diagnosis, as well as placebo pills prior to the second PDT treatment. Patients with VD deficiency will require 14 days of neoadjuvant D3, rather than just 5 days if the initial VD level is normal.

Source link: https://clinicaltrials.gov/ct2/show/NCT03467789


Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer

Pancreatic cancer is an aggressive disease with treatment choices that have limited success, so new treatment options are required. Paricalcitol is a man-made vitamin D that is believed to work by blocking a signal in the cancer tumor cells that leads to tumor formation and dissemination. Paricalcitol has not been approved by the FDA as a treatment for pancreatic cancer. In the intravenous formulation, Paricalcitol in the oral form will be administered three times a week, Paricalcitol in the oral formulation will be taken daily. The study is ongoing until disease progression, adverse event/toxicity, suicide, or some of the subject or sponsor discontinues the research. In this research report, the key objectives include: Investigate adverse side effects of paricalcitol's combination with gemcitabine and nab-paclitaxel. Evaluate overall survival in patients with pancreatic cancer treated with gemcitabine and nab-paclitaxel with or without paricalcitol.

Source link: https://clinicaltrials.gov/ct2/show/NCT03520790


A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy

According to previous studies, increased vitamin D levels in the blood is related to reduced brain inflammation in people with multiple sclerosis, a condition that is similar to cerebral demyelinating form ALD. However, if vitamin D levels are too high, serious side effects can occur. The current research is designed to provide a safe dose of vitamin D for boys with ALD. The researchers will also investigate whether or not vitamin D supplementation improves ALD boys' markers of oxidative stress and inflammation in the blood and brains. Starting doses will include 1,000 to 2,000 international units of vitamin D3 per day for a 6 month period, followed by a conditional rise to 2,000, 3,000, or 4,000 IU daily thereafter if vitamin D levels have not reached a target threshold. Participants will need to return every six months in order to finish a clinic visit and MRI of the brain with gadolinium, in keeping with the new standard of care for ALD boys aged 18mos - 25 years. Participants will have to submit blood tests every three months during the first year to ensure that the participants' calcium and vitamin D levels are within a safe range and to investigate the effects of vitamin D on markers in the blood. In order to test brain metabolites, the MRI protocol used during the first year will also include a new sequence.

Source link: https://clinicaltrials.gov/ct2/show/NCT02595489


Impact of Vitamin D3 Supplementation in Non-Sjogren Dry Eye Patients With Low Serum Vitamin D Level

Dry eye disease is a multifactorial, ocular inflammatory disorder that causes irritation, burning sensation, uneasiness, and blurring. Fat soluble vitamin D is a drug that fights inflammation, but deficiency can result in various chronic diseases, including dry eye. A prospective research was done in Rural health center Buchal Kalan on 108 patients with non-Sjogren dry eyes and low serum vitamin D levels. The purpose of this study was to determine vitamin D3 supplementation in treating non-Sjogren dry eye and conventional therapy alongside conventional therapy by using artificial tears in patients with hypovitaminosis D. Group 1 was only artificial tears 4 times/day, while the group 2 was given oral vitamin D3 supplementation of 6000 international units daily, as well as artificial tears. The effect of oral vitamin D3 supplementation on non-Sjogren dry eyes was evaluated by comparing means of ocular measurements of both groups over a period of time by using Mann-Whitney Test and Friedman Test.

Source link: https://clinicaltrials.gov/ct2/show/NCT05425914

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions